Dicerna Pharmaceuticals, Inc. (DRNA) Upgraded by Zacks Investment Research to “Buy”
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) was upgraded by Zacks Investment Research from a “strong sell” rating to a “buy” rating in a report issued on Monday. The brokerage currently has a $6.25 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target points to a potential upside of 14.26% from the stock’s previous close.
According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
Other equities analysts have also issued research reports about the stock. ValuEngine lowered shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Chardan Capital reaffirmed a “hold” rating on shares of Dicerna Pharmaceuticals in a research note on Monday, August 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $5.56.
Dicerna Pharmaceuticals (NASDAQ:DRNA) traded down 0.73% during midday trading on Monday, reaching $5.47. The company had a trading volume of 97,386 shares. The company’s market capitalization is $114.02 million. Dicerna Pharmaceuticals has a 52-week low of $2.42 and a 52-week high of $6.75. The company’s 50 day moving average is $4.91 and its 200-day moving average is $3.68.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.54). The business had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.08 million. Dicerna Pharmaceuticals had a negative return on equity of 168.65% and a negative net margin of 8,474.12%. The company’s quarterly revenue was up 2400.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.75) earnings per share. Equities analysts expect that Dicerna Pharmaceuticals will post ($2.70) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Dicerna Pharmaceuticals, Inc. (DRNA) Upgraded by Zacks Investment Research to “Buy”” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/23/dicerna-pharmaceuticals-inc-drna-upgraded-by-zacks-investment-research-to-buy.html.
A number of institutional investors have recently bought and sold shares of the stock. EcoR1 Capital LLC boosted its stake in Dicerna Pharmaceuticals by 101.0% in the 2nd quarter. EcoR1 Capital LLC now owns 767,992 shares of the biopharmaceutical company’s stock worth $2,435,000 after purchasing an additional 385,992 shares during the period. Palo Alto Investors LLC boosted its stake in Dicerna Pharmaceuticals by 4.0% in the 2nd quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock worth $1,588,000 after purchasing an additional 19,394 shares during the period. Renaissance Technologies LLC boosted its stake in Dicerna Pharmaceuticals by 2.4% in the 1st quarter. Renaissance Technologies LLC now owns 418,500 shares of the biopharmaceutical company’s stock worth $1,423,000 after purchasing an additional 9,818 shares during the period. Vanguard Group Inc. boosted its stake in Dicerna Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after purchasing an additional 14,517 shares during the period. Finally, UBS Group AG boosted its stake in Dicerna Pharmaceuticals by 0.6% in the 1st quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock worth $968,000 after purchasing an additional 1,599 shares during the period. 55.49% of the stock is owned by hedge funds and other institutional investors.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.